IGF1R and Diplopia: Similar to the results of teprotumumab (novel insulin-like growth factor I receptor antibody) in active TED (22, 23), as expected, MMF plus low-dose oral prednisolone showed the greatest effectiveness on CAS, proptosis and diplopia, and this factor significantly decreased during the study, and this decrease occurred earlier in CAS than proptosis and diplopia, suggesting that; MMF like teprotumumab was more efficient than corticosteroids in controlling local inflammation.